Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | AGER | Q15109 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL934289 | 0.85 | KMT2A (0.56) | TDP1ALDH1A1GAANPC1RAB9A | |
| SCHEMBL16935824 | 0.83 | ALDH1A1 (0.47) | SMN1; SMN2LMNAPKMKDM4ETDP1 | |
| SCHEMBL146157 | 0.82 | ALDH1A1 (0.62) | SMN1; SMN2LMNAPKMKDM4ETDP1 | |
| SCHEMBL7110016 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2LMNAPKMALDH1A1CYP2C9 | |
| SCHEMBL5660651 | 0.80 | ALDH1A1 (0.49) | SMN1; SMN2PKMKDM4EALDH1A1CYP2C9 | |
| SCHEMBL11504619 | 0.80 | ALDH1A1 (0.60) | SMN1; SMN2LMNAPKMKDM4ETDP1 | |
| SCHEMBL11504621 | 0.78 | ALDH1A1 (0.44) | SMN1; SMN2LMNAPKMKDM4ETDP1 | |
| SCHEMBL14580275 | 0.78 | HSD11B1 (0.57) | SMN1; SMN2PKMALDH1A1CYP2C9GAA | |
| SCHEMBL31544569 | 0.78 | HSD11B1 (0.57) | SMN1; SMN2PKMALDH1A1CYP2C9GAA | |
| SCHEMBL14040985 | 0.78 | ALDH1A1 (0.58) | SMN1; SMN2LMNAPKMKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1425262-B1 | Acylthiols and compositions thereof as anti-HIV and anti-retroviral agents | GOV OF USA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES NAT INST OF HEALTH (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8076372-B2 | Acythiols and component thiol compositions as anti-HIV and anti-retroviral agents | GOVERNMENT OF THE UNITED STATES (US) | 2011-12-13 | — | — | US | disclosed |
| US-20090247473-A1 | ACYTHIOLS AND COMPONENT THIOL COMPOSITIONS AS ANTI-HIV AND ANTI-RETROVIRAL AGENTS | THE GOVERNMENT OF THE U.S.A.,AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES (US) | 2009-10-01 | — | — | US | disclosed |
| US-7528274-B2 | Acylthiols and component thiol compositions as anti-HIV and anti-retroviral agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1425262-A4 | ACYLTHIOLS AND COMPONENT THIOL COMPOSITIONS AS ANTI-HIV AND ANTI-RETROVIRAL AGENTS | US GOV HEALTH & HUMAN SERV (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050020831-A1 | Acylthiols and component thiol compositions as anti-hiv and anti-retroviral agents | GOVERNMENT OF THE UNITED STATES | 2005-01-27 | — | — | US | disclosed |
| EP-1425262-A1 | ACYLTHIOLS AND COMPONENT THIOL COMPOSITIONS AS ANTI-HIV AND ANTI-RETROVIRAL AGENTS | The Gov. of USA, as represented by the Secretary, Dept. of Health and Human services, National Institutes of Health (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003014062-A1 | ACYLTHIOLS AND COMPONENT THIOL COMPOSITIONS AS ANTI-HIV AND ANTI-RETROVIRAL AGENTS | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-02-20 | — | — | WO | disclosed |
| US-6133270-A | Isothiazolones and pharmaceutical formulations | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| US-6001863-A | USEFUL AS ANTIVIRAL, ANTIINFLAMMATORY AND ANTIATHEROSCLEROSIS AGENT; ADMINISTERING TO THE PATIENT IN NEED OF ZINC EJECTION FROM NUCLEOCAPSID PROTEIN | WARNER-LAMBERT COMPANY (US) | 1999-12-14 | — | — | US | disclosed |
| US-5889034-A | ANTIINFLAMMATORY AGENT; ANTIATHEROSCLEROSIS AGENT; VIRICIDES | WARNER-LAMBERT COMPANY (US) | 1999-03-30 | — | — | US | disclosed |
| US-5734081-A | Arylthio compounds | WARNER-LAMBERT COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| US-5733921-A | ANTIRETROVIRAL AGENTS; ANTIINFLAMMATORY AGENTS; ANTIATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| EP-0828488-A1 | ISOTHIAZOLONES | WARNER-LAMBERT COMPANY (US) | 1998-03-18 | — | — | EP | disclosed |
| US-5668291-A | THIOSUBSTITUTED PYRIDINES, TREATMENT OF AIDS AND HIV | WARNER-LAMBERT COMPANY (US) | 1997-09-16 | — | — | US | disclosed |
| US-5668162-A | Isothiazolones lower plasma levels of lipoprotein(a) | WARNER-LAMBERT COMPANY | 1997-09-16 | — | — | US | disclosed |
| EP-0775110-A1 | ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-05-28 | — | — | EP | disclosed |
| US-5620997-A | VIRICIDES, ANTIINFLAMMATORY AGENTS, ANTIATHEROSCLEROTIC AGENT | WARNER-LAMBERT COMPANY (US) | 1997-04-15 | — | — | US | disclosed |
| WO-1996038144-A1 | ISOTHIAZOLONES | WARNER-LAMBERT COMPANY (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996004242-A1 | ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247473-A1 | ACYTHIOLS AND COMPONENT THIOL COMPOSITIONS AS ANTI-HIV AND ANTI-RETROVIRAL AGENTS | ZC3HAV1, ZFP3, ATL3 | SMN1; SMN2 3780/4885LMNA 4472/4885PKM 4166/4885 |
| US-20050020831-A1 | Acylthiols and component thiol compositions as anti-hiv and anti-retroviral agents | ZC3HAV1, ACAT2, ACAT1 | SMN1; SMN2 3835/4885LMNA 4523/4885PKM 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.